Evidence map›Paper›PMID 21537303›Full record

ArticleJournal of wound care2011

Wound healing following combined radiation and cetuximab therapy in head and neck cancer patients.

N R Dean, L Sweeny, P M Harari, J A Bonner, V Jones, L Clemons, H Geye, E L Rosenthal

Open access · greenAbstract read
In one paragraph

Article in Journal of wound care, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 18 citations in OpenAlex.

  1. Increased rates of local complication of central venous catheters in the targeted anticancer therapy era: a 2-year retrospective analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2015
    Article
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

N R DeanDepartment of Surgery, Division of Otolaryngology, University of Alabama in Birmingham, Alabama, USA.
L Sweeny
P M Harari
J A Bonner
V Jones
L Clemons
H Geye
E L Rosenthal
University of Alabama at Birmingham · USUniversity of Wisconsin–Madison · US

Funding

Research Training Program in Surgical OncologyT32CA091078 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KENNEDY, GREGORY DEAN · 2002 to 2017
$4.8M
CD147 as a Novel Target in Head and Neck CancerR01CA142637 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ROSENTHAL, EBEN L. · 2010 to 2014
$1.3M
NCI NIH HHS 2T32 CA091078-06NCI NIH HHS R01 CA142637NCI NIH HHS T32 CA091078
6 · The paper itself

Abstract

objectiveThis study set out to determine if cetuximab treatment increases the risk of wound healing complications when combined with radiation therapy.

methodWe performed a retrospective chart review of head and neck cancer patients who received salvage neck dissections between 1999 and 2007, at two academic tertiary care centres. Complications from wound healing were compared between radiation and combined therapy groups.

resultsA total of 35 patients received radiation (n=20) or combined radiation and cetuximab therapy (n=15) prior to neck dissection. The treatment groups were similar in regard to demographic and primary tumour-related characteristics. The time between treatment and salvage neck dissection did not differ between the radiation (3.9 months) and combination treatment (3.0 months) groups (p=0.15). Wound healing complications occurred in 13% (2/15) of the patients treated with radiation and cetuximab and there were no complications in patients who received radiation alone (p=0.20).

conclusionCetuximab did not significantly increase the risk of post-surgical wound complications, although a higher absolute number of wound complications was observed in the group treated with cetuximab and radiation therapy, compared with the group treated with radiation alone. CONFLICT OF INTEREST: This work was supported by a grant from the National Institute of Health (2T32 CA091078-06). One of the authors, JAB, is an occasional consultant and honoraria for ImClone and Bristol-Meyers Squibb.

Indexed as

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedCetuximabCombined Modality TherapyEpidermal Growth FactorHead and Neck NeoplasmsHumansRetrospective StudiesWound HealingAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedCetuximabEpidermal Growth Factor

Identifiers

PMID21537303
PMCPMC3951343
OpenAlexW2082475092

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.